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ndometrial carcinoma (EC) is a hall mark of gynecological malignancies that usually affects women 
above the age 50. It is one of the major causes of mortality in females with ever increasing 
prevalence and the mortality rate is 1.7 to 2.4 per 100000 and each year 10000 death occur due to 
ECs. MiRNAs regulate the expression of different proto-oncogenes and signaling pathways that are 
directly or indirectly involved in the development of cancer. Different miRNAs i.e. (miRNA-449, miRNA 
370, miRNA-424, and miRNA-152) which gets up or down regulated during endometrial cancer are the 
potential biomarkers for early diagnosis of EC. Targeting this relationship between the miRNA and 
signaling pathways may help in the development of new treatment in endometrial cancer. In current study, 
we reviewed literature from PubMed using miRNA and endometrial cancer as keywords and outlined the 
synthesis of potent miRNA and role of different miRNAs involved in ECs. The study revealed different 
sub types of miRNA played crucial role in the development of cancer by up and down regulation of 
different metabolic pathways. Many evidences have supported that miRNAs play role in control and 
regulation of different pathways leading to cancer and targeting these pathways may bring changes in the 
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Introduction  
Endometrial cancer (EC) affects 75% of women with 
post-menopausal [1,2]. It is highly prevalent and nearly 
found in 287,000 people worldwide [3]. Endometrial 
carcinoma can be classified in to two subtypes i.e. 
Endometriod endometrial carcinoma (Type-I) and non-
Endometriod endometrial carcinoma (Type-II) [4]. 
Type-I EC arises from eminent increase in the amount 
of circulating estrogen which is common in women after 
menopause. Broadly, type-I ECs can be distinguished on 
the basis of cytological examinations in to three major 
grades (G1 ≤ 6%, G2 is 5-50 and G3 > 50%) each with its 
own diagnostic features that are referred to as bench 
mark in diagnosis of Type I ECs [5].  
An elevated estrogen level down regulates the 
expression of phosphatase and tensin homolog PTEN 
that in turn initiate a plethora of molecular signaling 
pathways which facilitates transcription of oncogenic 
Kirsten rat sarcoma (K-ras). K-ras in turn accelerates the 
phosphorylation of estrogen receptor via activation of 
beta-catenin through increased level of Mitogen-
activated protein kinases (MAPK). This altered 
signaling drastically enhances cellular proliferation of 
endometrial tissue that leads to cancer. On the other 
hand, Type-II ECs are far more different from the Type-
I. As they are generally characterized after passing 
several stages of metastasis and are independent of 
estrogen levels [6]. Type-II ECs can be classified in to 
serous, clear cell differentiation or undifferentiated 
tumors [7].  Serous carcinoma falls under the category 
of Type-II ECs and are characterized by dyshesive 
polygonal cells that have high ratio of granules in 
cytoplasm. They are generally referred to as papillary 
tumors that affect females with age more or less five 
years greater than those suffering from Type-I ECs [8]. 
Clear cell differentiated endometrial carcinoma is a rare 
pathology that has characteristics similar to papillary 
tumors but differ by the presence of clear cytoplasm. 
Undifferentiated tumors are also termed as 
Carcinosarcoma that are quite prevalent among 
postmenopausal women [9]. They are diagnosed on the 
basis of mesenchymal components. Major therapy 
against this massive malignancy includes surgery which 
primarily involves excision of ovaries and other 
reproductive organs and other forms of treatment 
include adjuvant therapies that involve chemotherapy, 
radio therapy and hormonal therapies. These therapies 
have promising benefits yet the rate of recovery is quite 
often very slow and rate of relapse and recurrences is far 
greater then preventive cure [10]. 
The size of miRNAs are usually 10-25 base pair and 
have been confirmed to play an extensive role in cancer 
initiation, progression and metastasis [11]. Several of 
evidences have revealed the bifacial aspect of miRNAs in 
tumor environment. On the basis of their involvement 
in B-cell lymphoma, He et al demonstrated first time the 
oncogenic role of miRNAs. Their findings threw 
limelight on involvement of miRNA 17 polycistronic 
cluster in tumor progression, accelerated levels of 
miRNAs resulted in the hyper-expression of c-Myc 
causing tumor in induced B-cell Lymphoma mouse 
model. Furthermore, they set the foundation of 
classification of microRNAs in to onco-miRNAs and 
tumor suppressor miRNAs [12,13]. On these grounds it 
can be established that several miRNAs can act as 
oncogenic or tumor suppressor. However, numerous 
publications have implicated miRNAs as being 
suppressed in majority of cancer related pathologies [14-
16]. Owing to this global perception, scientists 
worldwide tried to investigate the role of miRNAs 
processing machinery (RNase III drosha and dicer in 
development of cancer. The RNase III drosha initiate the 
processes of miRNA synthesis where the dicer cleave the 
double strand RNA and miRNA in to short fragments 
[17-19]. Kumar et al conducted studies on mouse model 
of lung cancer, suggesting that miRNAs processing 
machinery has a pivotal role in tumor differentiation 
and metastasis, absence of any one of these can lead to 
preferential tumor growth in mice lacking either Drosha 
or Dicer1 [16]. 
Methods 
Search Strategy and Literature Selection Criteria 
In this study we searched data in PubMed, and PubMed 
Central by using keywords microRNA and endometrial 
cancer. This review primarily focused on synthesis of 
miRNAs and their involvement in EC.  
Discussion  
MiRNAs Biogenesis 
MiRNA biogenesis is regulated by TGF-β signaling 
pathway. In TGF- β mediated pathway the ligand bind 
with the TGF-β receptor which activate the R-Smads 
complex with common smads (Co-Smad) and transloc- 
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cated in to nucleus and alter the miRNA transcription 
[20]. Most of the miRNA genes transcribed as single or 
cluster from the intronic region of DNA. The newly 
synthesized pre-miRNA then go through further 
processing by micro processing complex that contain 
RNAse III enzyme Drosha and a RNA binding protein 
DGCR8 ( DiGeorge Syndrome critical region 8) that 
makes this molecules in to double stranded pre-miRNA, 
symbolized by its hairpin loop structure [21]. DROSHA 
contain two domain for RNAse III that consciously 
remove the long structure of pre-miRNA [22]. Then the 
Exportin protein (Xpo5) transport the pre-miRNA from 
the nucleus. These proteins carry two NLS (Nuclear 
Localizing Sequences) that helps in the transportation of 
pre-miRNA. The miRNA entering to the cytoplasm is 
further processed by another RNAse III enzyme called 
DICER1. The activity of Dicer1 is to transform pre-
miRNA in to mature miRNA consisting of leading 
strand [23]. The mature miRNA is then brimmed into 
the RNA induced complex that already carries 
Transactivation Responsive RNA Binding Protein 
(TRBP) and Arguanate proteins (AGO) [24]. The exact 
mechanism of TRBP is not well known but there are 
different views about the mechanism of the action of 
TRBP and AGO, the most appraisal view suggests that 
the TRBPs orchestrate the physiological binding of 
various types of AGO proteins with Dicer. The AGO 
mediate the cleave of the hairpin to yield ~23 nucleotide 
mature miRNA and the whole activity in turns in 
promote guiding strand to bind to the target [25,26].   
MiRNA silence the expression of target mRNA by 
degrading mRNA poly-A tail in the presence of GW-182 
and AGO-associating protein. Perturbed processing can 
lead to tumor progression and eventually cancer. There 
are certain steps in the microRNA processing which are 
considered to be pinnacle in maintaining normal gene 
silencing carried out by miRNAs. There are a number of 
factors which must be taken into consideration like 
genomic alterations, oncogenic factors and epigenetic 
modifications of histone proteins that alter normal 
processing of miRNAs and leads to aberrant expression 
of downstream targets of miRNAs to produce tumor 
[27]. Piling evidences have suggested the involvement of 
aberrant miRNA signaling in diverse gynecological 
malignancies strengthening the fact that miRNAs are 
produced as pre miRNAs molecules which are trimmed, 
cleaved and transformed into primary miRNA which 
are exported out of the cell and mature in to mature 
miRNA that with the aid of TRBP and AGO undermines 
the process of gene silencing. miRNAs serve as 
oncogenic or cancer suppressor depending upon their 
level of expression and concentration [28-30]. 
Subtypes of miRNA and their Potential Role in EC 
MiRNAs have substantial role as therapeutic target in 
ECs. Extensive research has been conducted to 
understand the multidimensional benefits of miRNAs in 
different cancer related pathologies which can aid in 
their diagnosis, prognosis and treatment with the recent 
advancements in the field of bioinformatics and 
molecular biology, myriads of opportunities have 
emerged to delineate therapeutic and structural prose of 
miRNAs.  
Jurcevic et al. studied the expression of miRNA in 
endometrial cancer and normal endometrial samples 
and found that there are 138 different miRNAs which 
are differential expressed in EC. This analysis of 
differential expression of miRNA will help in 
classification and prognosis of the ECs [31]. A list of 
several types of miRNA that are differential expressed in 
ECs and their associated pathway are given at the end. 
miRNA-101 and its potential role in ECs was 
investigated by Konno et al and reported that this 
inhibits the proliferation and induces apoptosis in EC 
cells. It also initiate the migration, and invasion of 
epithelial mesenchymal transition associated cancer cell 
migration and invasion, renege the sphere forming 
capacity and increase the chemosensitivity toward 
paclitaxel drug. MiRNA-101 potentially target the 
expression of EZH2, MCL-1 and FOS and thus inhibit 
the cell proliferation, invasion and self-renewal in 
endometrial cancer by silencing of multiple oncogenes. 
The studies suggested that miRNA-101 and 
EZH2/MCL-1/FOS are the potential target for 
therapeutic development [32].  
A study carried by Kaur et al using disease type model 
investigated the effects of epigenetic modifications on 
miRNAs expression profile. Investigation establish the 
crucial involvement of methylation in prognosis of early 
tumor differentiation, moreover methylation of  
miRNA-129b is inevitable for early endometrial 
tumorgenesis [33]. 
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In some studies it is reported that there are imbalance 
in the endometrial cell proliferation by unimpeded 
estrogen and mismatch repair (MMR) system. Banno et 
al showed that the both types of EC are due to 
methylation and mutation in different genes. In Type-I 
EC, hypermethylation of MMR gene hMLH1 and 
mutation in PTEN, β-catenin, K-ras gene while in Type-
II EC HER-2/neu and p53 are mutated and 
hypermethylation of SPRY2, RASSFIA, RSK4, CHFR 
and CDH1 and also methylation of some tumor 
silencing microRNA including miRNA-124, miRNA-
126, miRNA-137, miRNA-129-2, miRNA-152 and 
miRNA-491. The study suggested that both genetic and 
epigenetic mechanisms are involved in endometrial 
cancer. Mutation and methylation of MMR gene lead to 
activate different proto-oncogenes and mutation and 
methylation of MMR gene in germ cell which might lead 
to inherited and familial cancer. The study also 
suggested that targeting the MMR gene which might 
help in development of new treatment and diagnostic 
strategies [34]. Zhang et al, using EC Ishikawa cells, 
demonstrated that miRNA-205 down regulates the 
PTEN expression by binding to the 3ꞌ UTR region of 
PTEN, which leads to the inhibition of cellular apoptosis 
in endometrial cancer cells. The studies suggested that 
targeting this relationship between miRNA-205 and 
PTEN might be helpful in therapeutic strategies of EC as 
well [35]. miRNA-424, a tumor suppressor miRNA has 
been studied extensively for its diagnostic benefits. 
Owing to its high expression in ECs it has been 
estimated to have a critical role in the process of tumor 
suppression. miRNA-424 directly mediates tumor 
suppression in ECs by directly binding to G-protein 
couple estrogen receptor (GPER) resulting in activation 
Akt/PI3K rendering it passive to bind to the PTEN 
domain. This could aid in designing targeted therapy 
against ECs [36].  
The endogenous miRNA-234 also plays an important 
role in the EC suppression. miRNA-234 inhibits the 
proliferation and migration of EC stem cells by down 
regulation of protein O-glucosyltransferase expression 
and Notch signaling pathway protein. Gao et al also 
reported that the expression level of miRNA-234 
genomic imprinted miRNA cluster between EC stem 
cell (HuECSC) and human endometrial cancer cell were 
significantly different from each other. Their findings 
have clearly delineate the fact that miRNA-234 presence 
is mandatory for the development and maturation of 
endometrial cells and thus can be used as diagnostic 
marker while estimating the extent of ECs [37].  
Jang et al, using miRNA microarray to check the 
microRNA expression level in clear cell carcinomas, 
serous carcinomas and germ cell tumor, shed light on 
the differential expression of six miRNAs. They found 
that all three types of cancer had a varied amount of 
miRNA expression. However, miRNA-449 was under-
expressed in ovarian and uterine clear cell carcinomas, 
while the miRNA-302d was highly expressed in germ 
cell tumor suggesting the fact miRNA-449 has a 
suppressive role in all of classified tumors while miRNA-
302 aggravates the intensity of tumor [38]. In similar 
context Chen et al study the role of miRNA-370 in 
endometrial ovarian cancer. Their findings have 
suggested that miRNA-370 in IGROVI and TOV112D 
endometrial ovarian cancer cells inhibit the cellular 
viability and colony formation and increase the chemo 
sensitivity of endometrial ovarian cancer cell toward 
cDDP. Furthermore, they suggested that miRNA-370 
was also involved in the negative regulation of Endoglin 
(ENG). Owing to these ground breaking realities they 
concluded that the hypermethylation was the potential 
mechanism of miRNA epigenetic silencing [39,40].  
Up-regulated  Down-regulated  Associated pathway 
miR-9  miR-376c MAPK signaling pathway 
miR-9-3p  miR-424-3p 
miR-18a-3p miR-337-5p p53 signaling pathway  
miRNA-101 miRNA-152 
miR-135a  miR-370 ErbB signaling pathway 
miR-135b  miR-542-5p 
miR-182  miR-199b-5p Jak-STAT signaling 
pathway miR-183  miR-1247 
miR-200a-5p miR-758 Wnt signaling pathway 
miR-218  miR-377 
miRNA-302d miRNA-137 Notch signaling pathway 
protein miRNA-424 miRNA-129-2 
miR-429  miR-214 TGF-β signaling pathway 
miRNA-449a* miRNA-124,  
miRNA-449b* miRNA-126,  
Table 1: A list of differential expressed miRNA in EC and associated 
pathways 
*miRNA highly express in type one and low express in EC type II
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In conclusion of this discussion, EC is one of the major 
causes of death in women due to limited diagnosis and 
treatment facility. Majority of women suffering from 
this disease die each year due to poor prognosis and 
disease diagnosis. MiRNAs have shown to be a leading 
regulator of oncogenes as well as their expression. Tones 
of evidence that peep deep in to miRNAs functioning in 
cancer have revealed that miRNAs have a momentous 
role in tumor progression and inhibition. Some of the 
miRNA epigenetically silence the mismatch repair gene 
(MMR gene) that lead to inherited cancer. So role of 
miRNA is very important for the development of EC. 
Different sub types of miRNA were studied and each has 
played an important role in suppression and induction 
of tumor. Upgrading the accessibility of tumor silencer 
miRNAs is likewise a noteworthy hindrance that should 
be overcome and in accordance with this methodology, 
different Nano innovative systems must be utilized to 
enhance bioavailability and uptake of miRNAs at the 
objective destinations. The distributed date on miRNA 
in malignancy has extended at a momentous rate and 
their connections with infection firstly portrayed in 
2002 and soon get their significance as biomarker for 
forecast, conclusion and anticipation of various 
ailments. Point by point and exhaustive pre-clinical 
studies will enhance our comprehension of the still 
understudied parts of miRNAs in various diseases and 
subtypes. A further insight into miRNA profile can 
unfold and expand views about EC and can set new 
foundations in the disease diagnosis and cure.  
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